Company / PP&E (Net)
Gilead Sciences PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$5.6B
FY2025
5-year range
$5.1B / $5.6B
FY2021-FY2025
Trend
+3.5%
vs FY2024
Sector context
#8 of 193
Health Care
What the data says
Among 193 Health Care companies, Gilead Sciences is in the top 4% for pp&e (net). Improved from $5.3B to $5.6B over the past 2 years.
Based on SEC 10-K filings.
$5.6B in FY2025 with a 5-year CAGR of +2.4%. Top quartile in the Health Care sector.
Improved from $5.3B to $5.6B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +0.8%
- 5-Year CAGR
- +2.4%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 193This company $5.6B Sector average $777.6M
▼
+620.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.4%, indicating consistent growth.
- In FY2025, pp&e (net) increased 3.5% year-over-year.
- Ranks #8 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.6B | +3.5% |
| FY2024 | $5.4B | +1.8% |
| FY2023 | $5.3B | -2.9% |
| FY2022 | $5.5B | +6.9% |
| FY2021 | $5.1B | +3.1% |
| FY2020 | $5.0B | +10.3% |
| FY2019 | $4.5B | +12.4% |
| FY2018 | $4.0B | +21.6% |
| FY2017 | $3.3B | +15.0% |
| FY2016 | $2.9B | +25.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026